Pierre Johansen

Personal Details

First Name:	Pierre
Middle Name:
Last Name:	Johansen
Suffix:
RePEc Short-ID:	pjo381
	[This author has chosen not to make the email address public]

Citations

Many of the citations below have been collected in an experimental project, CitEc, where a more detailed citation analysis can be found. These are citations from works listed in RePEc that could be analyzed mechanically. So far, only a minority of all works could be analyzed. See under "Corrections" how you can help improve the citation analysis.

Blog mentions

As found by EconAcademics.org, the blog aggregator for Economics research:

1. Sandra Lopes & Pierre Johansen & Mark Lamotte & Phil McEwan & Anamaria-Vera Olivieri & Volker Foos, 2020. "External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions," PharmacoEconomics, Springer, vol. 38(10), pages 1123-1133, October.

   Mentioned in:

   1. Chris Sampson’s journal round-up for 12th October 2020
      by Chris Sampson in The Academic Health Economists' Blog on 2020-10-12 11:00:03
2. Michael Willis & Adam Fridhammar & Jens Gundgaard & Andreas Nilsson & Pierre Johansen, 2020. "Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Out," PharmacoEconomics, Springer, vol. 38(9), pages 953-969, September.

   Mentioned in:

   1. Rita Faria’s journal round-up for 14th September 2020
      by Rita Faria in The Academic Health Economists' Blog on 2020-09-14 11:00:07
3. Sandra Lopes & Pierre Johansen & Mark Lamotte & Phil McEwan & Anamaria-Vera Olivieri & Volker Foos, 2021. "Authors’ reply to Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions”," PharmacoEconomics, Springer, vol. 39(1), pages 137-138, January.

   Mentioned in:

   1. Chris Sampson’s journal round-up for 18th January 2021
      by Chris Sampson in The Academic Health Economists' Blog on 2021-01-18 12:00:03

Articles

1. Pierre Johansen & Daniel Howard & Ryan Bishop & Søren Ilsøe Moreno & Kristine Buchholtz, 2020. "Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements," PharmacoEconomics, Springer, vol. 38(5), pages 485-497, May.

   Cited by:

   1. Elliot B. Tapper & Jagpreet Chhatwal, 2020. "We are Not Meeting the Needs of Pharmacoeconomic Models of Nonalcoholic Steatohepatitis, But We Can," PharmacoEconomics, Springer, vol. 38(5), pages 427-429, May.

2. Sandra Lopes & Pierre Johansen & Mark Lamotte & Phil McEwan & Anamaria-Vera Olivieri & Volker Foos, 2020. "External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions," PharmacoEconomics, Springer, vol. 38(10), pages 1123-1133, October.

   Cited by:

   1. Bram L. T. Ramaekers & Ben Wijnen & Nigel Armstrong & Svenja Petersohn & Talitha Feenstra & Junfeng Wang & Manuela A. Joore, 2021. "Comment on “External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions”," PharmacoEconomics, Springer, vol. 39(1), pages 133-135, January.

3. Michael Willis & Adam Fridhammar & Jens Gundgaard & Andreas Nilsson & Pierre Johansen, 2020. "Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Out," PharmacoEconomics, Springer, vol. 38(9), pages 953-969, September.

   Cited by:

   1. Sandra Lopes & Pierre Johansen & Mark Lamotte & Phil McEwan & Anamaria-Vera Olivieri & Volker Foos, 2020. "External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions," PharmacoEconomics, Springer, vol. 38(10), pages 1123-1133, October.

4. Pierre Johansen & Jonas Håkan-Bloch & Aiden R. Liu & Peter G. Bech & Sofie Persson & Lawrence A. Leiter, 2019. "Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada," PharmacoEconomics - Open, Springer, vol. 3(4), pages 537-550, December.

   Cited by:

   1. Michael Willis & Adam Fridhammar & Jens Gundgaard & Andreas Nilsson & Pierre Johansen, 2020. "Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Out," PharmacoEconomics, Springer, vol. 38(9), pages 953-969, September.

5. Michael Willis & Pierre Johansen & Andreas Nilsson & Christian Asseburg, 2017. "Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)," PharmacoEconomics, Springer, vol. 35(3), pages 375-396, March.

   Cited by:

   1. Joan Gil & Antoni Sicras-Mainar & Eugenio Zucchelli, 2018. "Uncontrolled diabetes and health care utilisation: panel data evidence from Spain," The European Journal of Health Economics, Springer;Deutsche Gesellschaft für Gesundheitsökonomie (DGGÖ), vol. 19(6), pages 785-795, July.
   2. Michael Willis & Christian Asseburg & April Slee & Andreas Nilsson & Cheryl Neslusan, 2021. "Macrovascular Risk Equations Based on the CANVAS Program," PharmacoEconomics, Springer, vol. 39(4), pages 447-461, April.
   3. Nasuh C. Büyükkaramikli & Maureen P. M. H. Rutten-van Mölken & Johan L. Severens & Maiwenn Al, 2019. "TECH-VER: A Verification Checklist to Reduce Errors in Models and Improve Their Credibility," PharmacoEconomics, Springer, vol. 37(11), pages 1391-1408, November.
   4. Michael Laxy & Verena Maria Schöning & Christoph Kurz & Rolf Holle & Annette Peters & Christa Meisinger & Wolfgang Rathmann & Kristin Mühlenbruch & Katharina Kähm, 2019. "Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort," PharmacoEconomics, Springer, vol. 37(12), pages 1485-1494, December.
   5. Pierre Johansen & Jonas Håkan-Bloch & Aiden R. Liu & Peter G. Bech & Sofie Persson & Lawrence A. Leiter, 2019. "Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada," PharmacoEconomics - Open, Springer, vol. 3(4), pages 537-550, December.
   6. Sandra Lopes & Pierre Johansen & Mark Lamotte & Phil McEwan & Anamaria-Vera Olivieri & Volker Foos, 2020. "External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions," PharmacoEconomics, Springer, vol. 38(10), pages 1123-1133, October.

6. Adam Lundqvist & Katarina Steen Carlsson & Pierre Johansen & Emelie Andersson & Michael Willis, 2014. "Validation of the IHE Cohort Model of Type 2 Diabetes and the Impact of Choice of Macrovascular Risk Equations," PLOS ONE, Public Library of Science, vol. 9(10), pages 1-12, October.

   Cited by:

   1. Michael Laxy & Verena Maria Schöning & Christoph Kurz & Rolf Holle & Annette Peters & Christa Meisinger & Wolfgang Rathmann & Kristin Mühlenbruch & Katharina Kähm, 2019. "Performance of the UKPDS Outcomes Model 2 for Predicting Death and Cardiovascular Events in Patients with Type 2 Diabetes Mellitus from a German Population-Based Cohort," PharmacoEconomics, Springer, vol. 37(12), pages 1485-1494, December.
   2. Michael Willis & Adam Fridhammar & Jens Gundgaard & Andreas Nilsson & Pierre Johansen, 2020. "Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Out," PharmacoEconomics, Springer, vol. 38(9), pages 953-969, September.
   3. Michael Willis & Pierre Johansen & Andreas Nilsson & Christian Asseburg, 2017. "Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM)," PharmacoEconomics, Springer, vol. 35(3), pages 375-396, March.
   4. Åsa Ericsson & Divina Glah & Maria Lorenzi & Jeroen P Jansen & Adam Fridhammar, 2018. "Cost-effectiveness of liraglutide versus lixisenatide as add-on therapies to basal insulin in type 2 diabetes," PLOS ONE, Public Library of Science, vol. 13(2), pages 1-16, February.
   5. Pierre Johansen & Jonas Håkan-Bloch & Aiden R. Liu & Peter G. Bech & Sofie Persson & Lawrence A. Leiter, 2019. "Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada," PharmacoEconomics - Open, Springer, vol. 3(4), pages 537-550, December.
   6. Åsa Ericsson & Adam Lundqvist, 2017. "Cost Effectiveness of Insulin Degludec Plus Liraglutide (IDegLira) in a Fixed Combination for Uncontrolled Type 2 Diabetes Mellitus in Sweden," Applied Health Economics and Health Policy, Springer, vol. 15(2), pages 237-248, April.

More information

Research fields, statistics, top rankings, if available.

Statistics

Access and download statistics for all items

Corrections

All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. For general information on how to correct material on RePEc, see these instructions.

To update listings or check citations waiting for approval, Pierre Johansen should log into the RePEc Author Service.

To make corrections to the bibliographic information of a particular item, find the technical contact on the abstract page of that item. There, details are also given on how to add or correct references and citations.

To link different versions of the same work, where versions have a different title, use this form. Note that if the versions have a very similar title and are in the author's profile, the links will usually be created automatically.

Please note that most corrections can take a couple of weeks to filter through the various RePEc services.